A strategy of antigen incorporation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles

Vaccine

Volumn 30, Issue 50, 2012, Pages 7229-7237

  Lattanzi, Laura ^a   Federico, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cross presentation; Exosomes; Nef; Vesicular stomatitis virus G protein; Virus like particles

Indexed keywords

ANTIGEN; ENVELOPE PROTEIN; HYBRID PROTEIN; LENTIVIRUS VECTOR; NEF PROTEIN;

ANTIGENICITY; ARTICLE; BIOENGINEERING; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CROSS PRESENTATION; DRUG DELIVERY SYSTEM; EXOSOME; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; LENTIVIRINAE; MULTIVESICULAR BODY; MUTANT; PRIORITY JOURNAL; VIRUS LIKE AGENT; VIRUS STRAIN;

ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DRUG CARRIERS; EXOSOMES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MUTANT PROTEINS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; VACCINES, VIRUS-LIKE PARTICLE; VIROSOMES;

EID: 84869875541     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.010     Document Type: Article

References (38)

1. György B., Szabó T.G., Pásztói M., Pal Z., Misjak P., Aradi B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011, 68:2667-2688.
2. Mathivanan S., Ji H., Simpson R.J. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010, 73:1907-1920.
3. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
4. Gibbings D.J., Ciaudo C., Erhardt M., Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009, 11:1143-1149.
5. Chaput N., Théry C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2010, 33:419-440.
6. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005, 3:10.
7. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9.
8. Ruiss R., Jochum S., Mocikat R., Hammerschmidt W., Zeilder R. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells-a new option for the treatment of B-CLL. PLoS One 2011, 6:e25294.
9. Zhang J., Zhang Y., Luo C., Xia Y., Chen H., Wu X. Glycosyl-phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. Tumori 2010, 96:452-459.
10. Zhang Y., Luo C.L., He B.C., Zhang J.M., Cheng G., Wu H.X. Exosomes derived from IL-12- anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 2010, 36:133-140.
11. Delcayre A., Estelles A., Sperinde J. Exosome display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis 2005, 35:158-168.
12. Hartman Z.C., Wei J., Glass O.K., Guo H., Lei G., Yang X.Y., et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 2011, 29:9361-9367.
13. Foster J.L., Denial S.J., Temple B.R., Garcia J.V. Mechanisms of HIV-1 Nef function and intracellular signaling. J Neuroimmune Pharmacol 2011, 6:230-246.
14. Wang J.K., Kiyokawa E., Verdin E., Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 2000, 97:394-399.
15. Zheng Y.H., Plemenitas A., Linnemann T., Fackler O.T. Peterlin BM Nef increases infectivity of HIV via lipid rafts. Curr Biol 2011, 11:875-879.
16. Zheng Y.H., Plemenitas A., Fielding C.J., Peterlin B.M. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci USA 2003, 100:8460-8465.
17. Alexander M., Bor Y.C., Ravichandran K.S., Hammarskjold M.L., Rekosh D. Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity. J Virol 2004, 78:1685-1696.
18. Krautkramer E., Giese S.I., Gasteier J.E., Murany W., Fackler O.T. Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol 2004, 78:4085-4097.
19. Lenassi M., Cagney G., Liao M., Vaupotic T., Bartholomeeusen K., Cheng Y., et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010, 11:110-122.
20. Muratori C., Cavallin L.E., Krätzel K., Tinari A., De Milito A., Fais S., et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 2009, 6:218-230.
21. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059-7067.
22. Di Bonito P., Grasso F., Mochi S., Petrone L., Fanales-Belasio E., Mei A., et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 2009, 395:45-55.
23. Sistigu A., Bracci L., Valentini M., Proietti E., Bona R., Negri D.R.M., et al. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine 2011, 29:3465-3475.
24. Peretti S., Schiavoni I., Pugliese K., Federico M. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol Ther 2005, 12:1185-1196.
25. Russo V., Lunghi F., Fontana R., Bregni M. A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients. J Cancer 2001, 2:329-330.
26. Sparacio S., Pfeiffer T., Schaal H., Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001, 3:602-612.
27. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., et al. Human gene MAGE-A3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179:921-930.
28. Alessandrini L., Santarcangelo A.C., Olivetta E., Ferrantelli F., d'Aloja P., Pugliese K., et al. T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. J Gen Virol 2000, 81:2905-2917.
29. Muratori C., D'Aloja P., Superti F., Tinari A., Sol-Foulon N., Sparacio S., et al. Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol 2006, 6:52.
30. Rabesandratana H., Toutant J.P., Reggio H., Vidal M. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes. Blood 1998, 91:2573-2580.
31. Nguyen D.H., Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000, 74:3264-3272.
32. Briggs J.A., Simon M.N., Gross I., Krausslich H.G., Fuller S.D., Vogt V.M., et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 2004, 11:672-675.
33. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
34. Van den Eynde B.J., Van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693.
35. Feng D., Zhao W.L., Ye Y.Y., Bai X.C., Liu R.Q., Chang L.F., et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic 2010, 11:675-687.
36. Segura M.M., Garnier A., Durocher Y., Ansorge S., Kamen A. New protocol for lentiviral vector mass production. Methods Mol Biol 2010, 614:39-52.
37. Tan A., De La Peña H., Seifalian A.M. The application of exosomes as a nanoscale cancer vaccine. Int J Nanomedicine 2010, 5:889-900.
38. Lamparski H.G., Metha-Damani A., Yao J.Y., Patel S., Hsu D.H., Ruegg C., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270:211-226.